Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Cannon

Showing results (51-60 of 149) with videos related to

Pageof 15
Sort By:
Journal of Clinical Pharmacology|July 7, 1999
Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndromeN B Modi, W Novotny, J D Reimann, et al.
Circulation|November 9, 2000
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudyH V Barron, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|March 7, 2001
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 InvestigatorsC P Cannon, C H McCabe, R G Wilcox, et al.
Alimentary Pharmacology & Therapeutics|July 15, 2009
Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelinesL Laine, L Connors, M R Griffin, et al.
International Journal of Clinical Practice|April 2, 2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trialS Husted, R A Harrington, C P Cannon, et al.
The Journal of Emergency Medicine|August 8, 1998
Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effectM J Sagarin, C P Cannon, M S Cermignani, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarctionN B Modi, S Eppler, J Breed, et al.
Circulation|February 17, 1999
Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteersC P Cannon, J Dingemanse, C H Kleinbloesem, et al.
The American Journal of Cardiology|February 1, 1995
How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial)D Zahger, B Cercek, C P Cannon, et al.
Blood|November 24, 2001
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromesF F O'Connor, D C Shields, A Fitzgerald, et al.
Pageof 15

Showing results (51-60 of 149) with videos related to

Sort By:
Pageof 15
Journal of Clinical Pharmacology|July 7, 1999
Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndromeN B Modi, W Novotny, J D Reimann, et al.
Circulation|November 9, 2000
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudyH V Barron, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|March 7, 2001
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 InvestigatorsC P Cannon, C H McCabe, R G Wilcox, et al.
Alimentary Pharmacology & Therapeutics|July 15, 2009
Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelinesL Laine, L Connors, M R Griffin, et al.
International Journal of Clinical Practice|April 2, 2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trialS Husted, R A Harrington, C P Cannon, et al.
The Journal of Emergency Medicine|August 8, 1998
Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effectM J Sagarin, C P Cannon, M S Cermignani, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarctionN B Modi, S Eppler, J Breed, et al.
Circulation|February 17, 1999
Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteersC P Cannon, J Dingemanse, C H Kleinbloesem, et al.
The American Journal of Cardiology|February 1, 1995
How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial)D Zahger, B Cercek, C P Cannon, et al.
Blood|November 24, 2001
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromesF F O'Connor, D C Shields, A Fitzgerald, et al.
Pageof 15